-
Ceruletide Workflows for Pancreatic Research
2026-09-24
Use Ceruletide (Caerulein) to build controlled pancreatic stimulation and gastrointestinal motility assays, then connect injury readouts to emerging antifibrotic research. This practical guide separates pilot assay conditions from published evidence and explains how to optimize peptide handling, controls, and interpretation.
-
BoNT/A, SOCS3, and Ocular Angiogenesis
2026-09-23
A mouse study found that intravitreal botulinum neurotoxin serotype A (BoNT/A) reduced laser-induced choroidal neovascularization and glial activation, alongside increased Socs3 and decreased Vegfa expression. Results from SOCS3-deficient mice suggest that neuronal or glial SOCS3 contributes to this protection, offering a preclinical perspective on neuroglial regulation of pathological angiogenesis.
-
STL427944 Targets FOXM1 to Overcome Chemoresistance
2026-09-23
The reference study identifies STL427944 through gene-network analysis and shows that it suppresses FOXM1 by moving the protein from the nucleus to the cytoplasm, where it undergoes autophagy-dependent degradation. This mechanism selectively attenuated FOXM1-associated transcriptional programs and sensitized human cancer cells to platinum agents, 5-fluorouracil, and taxanes.
-
CKI 7 dihydrochloride: CK1 Assay Workflows
2026-09-22
Build cleaner biochemical and cell-based experiments with CKI 7 dihydrochloride, a selective Casein kinase 1 inhibitor for pathway dissection. This guide connects dosing, controls, Wnt and circadian assays, apoptosis readouts, and the MAPK10–KRT16 metastasis study without conflating distinct kinase systems.
-
APEX2 Supports TERT Expression in Human Stem Cells
2026-09-22
A 2024 bioRxiv preprint identifies APEX2 as a DNA repair factor required for efficient TERT expression and telomerase activity in human embryonic stem cells and a melanoma cell line. RNA-seq and chromatin immunoprecipitation connect this effect to repetitive DNA, especially MIR elements near TERT intron 2, offering a mechanistic link between genome maintenance and telomerase regulation.
-
Dual HER2–VEGFR-2 Targeting in TNBC
2026-09-21
The 2026 reference study examines Lapatinib and Telatinib as a dual tyrosine kinase inhibition strategy in HER2-negative MDA-MB-231 triple-negative breast cancer cells. Its main contribution is phenotype-first evidence linking treatment with reduced invadopodia formation, cell proliferation, and two-dimensional tube formation, while also highlighting the difficulty of assigning direct receptor-specific mechanisms in a receptor-negative model.
-
PARP1/FAK/COL5A1 Drives Ovarian Cancer EMT
2026-09-21
The reference study establishes a cholesterol-resistant ovarian cancer model and identifies PARP1/FAK/COL5A1 signaling as a mechanistic link between chronic cholesterol exposure, EMT, and tumorigenesis. Its combination of long-term adaptation, pathway analysis, genetic depletion, pharmacologic perturbation, and in vitro and in vivo testing provides a useful framework for cancer biology research and FAK pathway interrogation.
-
KCNE4 Shapes Kv1.3 Blocker Pharmacology
2026-09-20
The reference study shows that the leukocyte auxiliary subunit KCNE4 changes how Kv1.3 responds to the intracellular blocker Psora 4 without measurably changing blocker affinity. By separating affinity from inhibition kinetics and comparing extracellular and intracellular channel blockers, the work provides a mechanistic framework for interpreting Kv1.3 pharmacology in immune-cell models.
-
Acetylcysteine in Patient-Specific Tumor Models
2026-09-19
Acetylcysteine can serve as a mechanistic redox perturbation in patient-derived organoid–fibroblast systems. This article explains how to interpret N-acetyl-L-cysteine responses in multicellular pancreatic cancer assays without confusing antioxidant activity with proof of chemosensitization.
-
SAG as a Translational Hedgehog Control Point
2026-09-18
SAG is more than a pathway-on reagent: it is a mechanistic control for separating ligand, Smoothened, and downstream Hedgehog biology. This thought-leadership guide connects SAG assay design with developmental modeling, stem cell maintenance research, tumorigenesis studies, and neuroregeneration while defining practical boundaries for translation.
-
APOL1 Evolution, Isoforms, and APOL3 Interaction
2026-09-18
The reference study integrates APOL1 molecular evolution, splice-isoform biology, and APOL3 interaction to refine explanations for variant-associated cellular injury. Its main practical implication is that APOL1 risk-variant experiments should preserve haplotype context, isoform identity, and protein-interaction state rather than treating APOL1 as a single uniform entity.
-
Renal K+ Channels in Septic Shock
2026-09-17
This study shows that renal potassium-channel blockade does not simply restore vasoconstrictor activity during sepsis: glibenclamide and iberiotoxin instead intensified agonist-associated reductions in renal blood flow in a time-dependent setting. Its paired isolated-kidney and in vivo design provides a useful framework for interpreting channel subtype effects, vascular reactivity, and the risks of combining channel blockers with pressor agents.
-
Pulsed Plasma Degradation of Sulfamonomethoxine
2026-09-17
The reference study shows that pulsed plasma discharge can degrade Sulfamonomethoxine (SMM) in aqueous solution with first-order kinetics and energy-dependent removal. Its central practical contribution is the combined assessment of degradation products and algal toxicity, revealing that treatment-generated hydrogen peroxide can remain hazardous even after the antibiotic declines.
-
BAP1, SLC7A11, and Disulfidptosis in Cancer
2026-09-16
The 2024 Oncogenesis study identifies BAP1 as a suppressor of glucose starvation-induced disulfidptosis, linking its regulation of SLC7A11 to cystine stress and NADPH availability. The findings clarify how BAP1 can oppose disulfidptosis while promoting other regulated cell-death programs, creating a framework for studying redox vulnerabilities in cancer cells.
-
Phenacetin as a Translational PK Benchmark
2026-09-16
A thought-leadership guide to using Phenacetin as a controlled pharmacokinetic research probe, with mechanistic context, solvent and stability guidance, safety boundaries, and a translational framework informed by PDK4 inhibitor development.